Form 4: Intellia Director Buys 150,000 Shares in Open Market

Intellia Therapeutics Director Fred E Cohen purchased 150,000 shares of common stock on January 5, 2026, increasing his beneficial ownership.

Summary

• Fred E Cohen, a Director of Intellia Therapeutics, Inc. (NTLA), acquired 150,000 shares of common stock.
• The transaction occurred on January 5, 2026, as an open market purchase.
• The shares were bought at a weighted average price of $9.35 per share.
• Individual transaction prices for the shares ranged from $9.13 to $9.68.
• Following this purchase, Mr. Cohen beneficially owns a total of 207,453 shares of Intellia Therapeutics common stock.

Sentiment

Score: 8

Explanation: The significant open market purchase by a director indicates strong insider confidence in the company's valuation and future prospects, which is generally a very positive signal for investors.

Positives

• A director's open market purchase of a significant number of shares (150,000) indicates strong insider confidence in the company's future prospects.
• The increase in beneficial ownership to 207,453 shares aligns the director's interests more closely with those of other shareholders.

Future Outlook

The filing does not contain forward-looking statements or guidance, as it is a report of an insider transaction.

Industry Context

Insider buying, especially by a director, can be seen as a positive signal in the biotechnology sector, which often involves long development cycles and significant R&D investments. It suggests internal confidence in the company's pipeline or strategic direction, potentially differentiating it from competitors facing similar challenges.

Comparison to Industry Standards

• While specific comparable companies or projects are not mentioned in this filing, a director's open market purchase of 150,000 shares at a weighted average price of $9.35 is a substantial investment.
• This level of insider commitment is generally viewed favorably, as it aligns the director's financial interests with those of other shareholders, a practice considered a positive governance standard across industries, including biotech.

Stakeholder Impact

• Shareholders: The purchase by a director may instill greater confidence in the company's stock, potentially leading to positive sentiment and increased demand.
• Employees: A director's investment can signal stability and a positive future outlook, potentially boosting employee morale.

Key Dates

Recommendation

The significant open market purchase of 150,000 shares by a director, Fred E Cohen, at a weighted average price of $9.35, strongly suggests insider confidence in Intellia Therapeutics' future performance and valuation. Such a substantial investment aligns management's interests with shareholders and is typically a bullish indicator, warranting a 'buy' recommendation for investors seeking to capitalize on this positive signal.

Keywords

Intellia Therapeutics, NTLA, Insider Buying, Director Purchase, Stock Acquisition, Form 4, Biotechnology, Gene Editing